Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.77 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.64 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.57 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.57 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.57 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | MPO | P05164 | 8/20 | 0.73 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.73 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL32678244 | 1.00 | HTR2A (0.97) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| Hydrochloric Acid SCHEMBL32678247 | 1.00 | HTR2A (0.97) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| SCHEMBL30952647 | 0.98 | HTR2A (1.00) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| SCHEMBL743153 | 0.98 | HTR2A (1.00) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| SCHEMBL28368250 | 0.98 | HTR2A (1.00) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| Methane SCHEMBL274681 | 0.97 | HTR2A (0.97) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| SCHEMBL17819282 | 0.97 | HTR2A (0.97) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| Cyanide SCHEMBL28691191 | 0.94 | HTR2A (0.91) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| Oxalic Acid SCHEMBL2539797 | 0.90 | HTR2A (0.83) | HTR2AKMT2AHTR1AMPOTRPM8 | |
| Hydrochloric Acid SCHEMBL1967285 | 0.87 | HTR1A (1.00) | HTR2AKMT2AHTR1AMPOTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | CAAMTECH, INC. | 2024-08-22 | — | — | US | claimed |
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2025-02-11 | — | — | US | disclosed |
| US-20240327350-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | CAAMTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3841102-B1 | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022163041-A1 | INDOLE-STRUCTURE-SELECTIVE REACTION AGENT, INDOLE-STRUCTURE-SELECTIVE CROSSLINKING AGENT, AND METHOD FOR PRODUCING COMPOSITE USING THESE | 株式会社カネカ | 2022-08-04 | — | — | WO | disclosed |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG, INC. | 2022-07-07 | — | — | US | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-5563147-A | CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0705832-A1 | Serotonergic modulators | LILLY INDUSTRIES LIMITED (GB) | 1996-04-10 | — | — | EP | disclosed |
| EP-0520987-A1 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO-$g(b)-CARBOLINE DERIVATIVES | NEUREX CORPORATION (US) | 1993-01-07 | — | — | EP | disclosed |
| US-5169852-A | Anorexigenic agents | NEUREX CORPORATION (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0520987-A4 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO--g(b)-CARBOLINE DERIVATIVES. | NEUREX CORP (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4978669-A | ALTERING MACRONUTRIENT PREFERENCE | NEUREX CORPORATION (US) | 1990-12-18 | — | — | US | disclosed |
| WO-1990014827-A1 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO-β-CARBOLINE DERIVATIVES | NEUREX CORPORATION (US) | 1990-12-13 | — | — | WO | disclosed |
| US-4361566-A | Tetrahydro β-carbolines having antihypertensive activity | MILES LABORATORIES, INC. (US) | 1982-11-30 | — | — | US | disclosed |
| US-4291039-A | Tetrahydro β-carbolines having anti-hypertensive activity | MILES LABORATORIES, INC. (US) | 1981-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | HTR2A 3926/4885HTR1A 4374/4885HTR2C 3782/4885 |
| US-20220213036-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | HTR2A 3926/4885HTR1A 4374/4885HTR2C 3782/4885 |
| US-11834411-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | HTR2A 3926/4885HTR1A 4374/4885HTR2C 3782/4885 |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | HTR2A 3926/4885HTR1A 4374/4885HTR2C 3782/4885 |
| US-20240327350-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | HTR2A 3926/4885HTR1A 4374/4885HTR2C 3782/4885 |
| US-12221439-B2 | Tetrahydropyridopyrimidine derivatives as AhR modulators | AHR, ARNT, NQO1 | HTR2A 526/4885HTR1A 580/4885HTR2C 514/4885 |
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | SLC6A4, HTR2A, CMA1 | HTR2A 2/4885HTR1A 11/4885HTR2C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.